Results 101 to 110 of about 78,382 (206)

Polyamine and EIF5A hypusination downstream of c-Myc confers targeted therapy resistance in BRAF mutant melanoma

Molecular Cancer
Background BRAF inhibitors are widely employed in the treatment of melanoma with the BRAF V600E mutation. However, the development of resistance compromises their therapeutic efficacy.
Byung-Sun Park, Heeju Jeon, Yeonseo Kim, Haejin Kwon, Ga-Eun Choi, Sung-Gil Chi, Hyun-Mee Park, Hyunbeom Lee, Tackhoon Kim   +8 more
doaj   +1 more source

Prospects for non-immunological molecular therapeutics in melanoma [PDF]

, 2010
In 2006 there were 60,000 new cases of cutaneous melanoma in the European Union and 13,000 deaths (www.europeancancerleagues.org). Currently available systemic treatment options for metastatic melanoma, including both cytotoxic and immunologic therapies,
Crown, John, Eustace, Alexander J., Mahgoub, Thamir, O'Donovan, Norma, Tryfonopoulos, Dimitrios   +4 more
core  

Pan-RAF inhibitor exarafenib targets BRAF class II/III NSCLC and reveals ARAF-KSR1 resistance and combination strategies

Nature Communications
Oncogenic BRAF mutations, including those in non-small cell lung cancer (NSCLC), are classified as Class I, II, or III. While approved therapies exist for BRAF Class I mutants, no approved therapies exist for Class II and III BRAF-mutated NSCLC. Analysis
Tadashi Manabe, Hannah C. Bergo, Qingtian Li, Tim Sen Wang, Paul Severson, Nichol Miller, Catherine Lee, Elifnur Yay Donderici, Nicole Zhang, Wei Wu, Yu-Ting Chou, Daniel L. Kerr, Paul Allegakoen, Kathryn B. Grandinetti, Liliana Soroceanu, Robert J. Pelham, Eric S. Martin, Eric A. Murphy, Vishesh Khanna, Joel W. Neal, Christopher T. Chen, Shumei Kato, Richard Williams, Trever G. Bivona   +23 more
doaj   +1 more source

BRAF Inhibitor LUT014 [PDF]

, 2020
openaire   +1 more source

BRAF Inhibitor PLX8394 [PDF]

, 2020
openaire   +1 more source

Microparticle-Delivered Cxcl9 Prolongs Braf Inhibitor Efficacy in Melanoma. [PDF]

Cancer Immunol Res, 2023
Romano G, Paradiso F, Li P, Shukla P, Barger LN, El Naggar O, Miller JP, Liang RJ, Helms TL, Lazar AJ, Wargo JA, Taraballi F, Costello JC, Kwong LN.   +13 more
europepmc   +1 more source

A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor [PDF]

, 2017
et al,, Tan, Benjamin R
core   +2 more sources

BRAF inhibitor resistance in melanoma: from resistance mechanisms to therapeutic innovations. [PDF]

Mol Biomed
Shang Y, Cao T, Li J, Li J, Zhang L, Ma Q, Feng L, Zhao H.   +7 more
europepmc   +1 more source

Activation of the JAK/STAT Pathway Leads to BRAF Inhibitor Resistance in BRAFV600E Positive Thyroid Carcinoma. [PDF]

Mol Cancer Res, 2023
Limberg J, Egan CE, Gray KD, Singh M, Loewenstein Z, Yang Y, Riascos MC, Al Asadi H, Safe P, El Eshaky S, Liang H, Ullmann TM, Wang W, Li W, Zhang T, Xiang J, Stefanova D, Jin MM, Zarnegar R, Fahey TJ, Min IM.   +20 more
europepmc   +1 more source

Molecular Basis of BRAF Inhibitor Resistance in Melanoma: A Systematic Review. [PDF]

Pharmaceuticals (Basel)
Cosci I, Salizzato V, Del Fiore P, Pigozzo J, Guarneri V, Mocellin S, Ferlin A, Mathlouthi S, Piccin L, Garofalo M.   +9 more
europepmc   +1 more source